Jury Awards Ariad $65.2M In Lilly Patent Feud

Law360, New York (May 4, 2006, 12:00 AM EDT) -- In the latest development in a long-running legal battle, a federal jury has awarded at least $65.2 million to Ariad Pharmaceuticals Inc. after finding that Eli Lilly and Co.’s osteoporosis drug Evista and septic shock drug Xigris infringed on an Ariad patent.

The patent at issue in the case, U.S. Patent No. 6,410,516, is owned by the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research and the President and Fellows of Harvard College, and is licensed to Ariad.

Kineret is used to treat pain...
To view the full article, register now.